JPMorgan Chase & Co. cut shares of Hikma Pharmaceuticals (LON:HIK – Get Rating) to a neutral rating in a research note published on Wednesday, Marketbeat Ratings reports. They currently have GBX 1,900 ($23.91) price target on the stock, down from their prior price target of GBX 2,900 ($36.49).
Several other equities analysts have also issued reports on HIK. Barclays reissued an overweight rating and issued a GBX 2,500 ($31.46) price target on shares of Hikma Pharmaceuticals in a research note on Tuesday, May 24th. Morgan Stanley reissued an equal weight rating on shares of Hikma Pharmaceuticals in a research note on Wednesday, May 11th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of Hold and a consensus price target of GBX 2,444.29 ($30.76).
Hikma Pharmaceuticals stock opened at GBX 1,688.50 ($21.25) on Wednesday. The stock’s 50 day moving average is GBX 1,924.78 and its 200 day moving average is GBX 2,046.94. The company has a debt-to-equity ratio of 34.29, a current ratio of 2.06 and a quick ratio of 1.31. The firm has a market cap of £3.75 billion and a P/E ratio of 11.79. Hikma Pharmaceuticals has a one year low of GBX 1,631.50 ($20.53) and a one year high of GBX 2,703 ($34.01).
Hikma Pharmaceuticals Company Profile (Get Rating)
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded.
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.